CALGARY, May 15 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing insulin and other metabolic and cardiovascular protein-based pharmaceuticals and a series of non-pharmaceutical products, today announced that its President and CEO, Andrew Baum, was named as an officer of the Biotechnology Industry Organization (BIO) Board of Directors for the 2007/2008 year. In his new role Mr. Baum will serve as Secretary of the BIO Board as well as Vice Chair, Food & Agriculture. Mr. Baum will continue to fulfill his existing role as a Director of the Board and Chair of the Food & Agriculture Committee.
“I would like to congratulate Andrew Baum on his recent appointment as an officer of the Board of Directors of BIO,” said Richard Smith, Chairman of the Board of Directors of SemBioSys. “While the membership of BIO will gain the benefit of Andrew’s enthusiasm and extensive knowledge of the biotechnology industry, SemBioSys will in turn gain great benefit from the experience and network developed by Andrew as we continue to advance our pipeline of pharmaceutical and non-pharmaceutical products.”
“I welcome the opportunity to work with other members of the biotechnology industry toward the development and advancement of new life-saving and life-enhancing drugs and diagnostics,” said Andrew Baum. “In particular, I am looking forward to contributing to the knowledge and awareness of food and agriculture to the biotech industry from the unique perspective as an executive of a company that integrates agricultural and medical biotechnology.”
BIO represents more than 1,100 biotechnology companies, academic institutions, state and provincial biotechnology centers and related organizations across the United States, Canada and 30 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the global event for biotechnology.
About SemBioSys Genetics Inc. (www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing insulin and other protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company’s lead candidate is recombinant human insulin produced in the plant host safflower, to serve the rapidly expanding global diabetes market and to supply insulin for inhalation and other alternative insulin delivery technologies. The Company’s other protein-based pharmaceutical candidate is a cardiovascular drug called Apo AI. SemBioSys is also developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and other similar expressions which constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company’s ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.
SemBioSys Genetics Inc.
CONTACT: SemBioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:bauma@sembiosys.com, Internet: www.sembiosys.com; Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail: rmarshall@equicomgroup.com
